Showing 141-150 of 1560 results for "".
The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
https://reachmd.com/programs/project-oncology/the-transition-from-pediatric-to-adult-care-for-patients-with-sickle-cell-disease/36448/Effective transition from pediatric to adult care should begin as early as age twelve for patients with sickle cell disease, incorporating factors like education, self-advocacy skills, and support from transition care coordinators. Tune in to hear Dr. Nidhi Bhatt, who works in the Department of HemaSickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies
https://reachmd.com/programs/project-oncology/sickle-cell-disease-care-balancing-disease-modifying-and-curative-therapies/36488/Despite the promise of curative therapies for sickle cell disease, access and cost barriers highlight the ongoing need for disease-modifying treatments like hydroxyurea. Tune in to hear Dr. Yogindra Persuad, a physician in the Department of Hematology at St. Jude Children’s Research Hospital in MempImproving Health Literacy to Empower Adolescents With Sickle Cell Disease
https://reachmd.com/programs/project-oncology/improving-health-literacy-to-empower-adolescents-with-sickle-cell-disease/35927/Health literacy directly influences outcomes for patients with sickle cell disease, especially during the critical transition from pediatric to adult care. Validated tools to help assess comprehension and simplified, patient-informed education materials are essential for optimal care. HearAdvances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
https://reachmd.com/programs/project-oncology/advances-in-follicular-lymphoma-treatment-car-t-cell-therapys-evolving-role/36486/As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adAdvances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
https://reachmd.com/programs/project-oncology/advances-in-follicular-lymphoma-treatment-car-t-cell-therapys-evolving-role/35485/As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adUnlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
https://reachmd.com/programs/project-oncology/unlocking-tumor-complexity-single-cell-rna-sequencing-in-lung-cancer/36553/Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diverImproving CAR T Referrals for Large B-Cell Lymphoma: A Path to Better Collaboration
https://reachmd.com/programs/project-oncology/improving-car-t-referrals-for-large-b-cell-lymphoma-a-path-to-better-collaboration/33232/For patients with relapsed/refractory large B-cell lymphoma, timely access to CAR T-cell therapy can be life-saving, but communication gaps between referring physicians and CAR T centers can lead to delays or missed opportunities. Fortunately, practical strategies like building strong referral netwoAnalyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
https://reachmd.com/programs/project-oncology/analyzing-toxicity-trends-post-car-t-cell-therapy-implications-for-patient-monitoring/35454/Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconomic barrier remains: patients are typically required to stay near a certified treatment center for at least 4 weeks after infusion to manage potential adverse events. So to help imprImmunotherapy Advances in Squamous Cell Anal Carcinoma: A New Standard of Care
https://reachmd.com/programs/project-oncology/immunotherapy-advances-in-squamous-cell-anal-carcinoma-a-new-standard-of-care/34983/Recent updates are redefining treatment expectations for squamous cell carcinoma of the anal canal, with immunotherapy now playing a central role. In fact, pivotal data from the phase 3 POD1UM-303 trial led to the FDA approval of retifanlimab in combination with carboplatin and paclitaxel, which isEvolving Strategies in Limited-Stage Small Cell Lung Cancer Management
https://reachmd.com/programs/deep-breaths-updates-chest/evolving-strategies-in-limited-stage-small-cell-lung-cancer-management/32963/Recent therapeutic advances are reshaping our approach to limited-stage small cell lung cancer. In this multidisciplinary discussion, Dr. Gerard Silvestri sits down with Drs. Adam Fox, Mariam Alexander, and Anurag Singh to explore the evolving standard of care and practical considerations for timely